BioMimetic Ships Augment Bone Graft (NASDAQ:BMTI)

BioMimetic Therapeutics Inc (NASDAQ:BMTI) has announced that they have shipped their first order of Augment Bone Graft to their Canadian distributor, Joint Solutions Alliance Corporation. Joint Solutions is a sales and distribution company for orthopedic products headquartered in Ontario, Canada and is the exclusive distributor of BioMimetic’s Augment Bone Graft in Canada.

@@AdsenseRight@@ Previously released data shows, that with the use of Augment, patients can expect a comparable treatment outcome while being spared the pain and potential morbidity associated with traditional autograft bone harvesting and transplantation. Augment is a completely synthetic grafting system for bone regeneration and is composed of a purified recombinant growth factor, recombinant human platelet derived growth factor (rhPDGF-BB), and a synthetic calcium phosphate matrix, beta-tricalcium phosphate (β-TCP). The combination of the two components of Augment is the key to the overall effectiveness of the product.

BioMimetic Therapeutics is one of the leading biotechnology companies utilizing purified recombinant human platelet-derived growth factor (rhPDGF-BB) in combination with tissue specific matrices as its primary technology platform for promotion of tissue healing and regeneration. The Company has completed and ongoing clinical trials with its product candidates Augment and Augment Injectable in multiple orthopedic bone healing indications including the treatment of foot and ankle fusions and the stimulation of healing of fractures of the wrist. BioMimetics Therapeutics’ COO, Steven Hirsch said that they are really excited about the shipment and sale of Augment Bone Graft to Canada which would be their first commercial success and opportunity within orthopedics.